Johnson & Johnson
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-57.9% vs price
Base Case (Median)
-39.9% vs price
Bull Case (75th pct.)
-9.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $80.46 | -68.6% | High (40%) |
| PE Comparable | $196.28 | -23.4% | Medium (25%) |
| Growth Trajectory DCF | $267.19 | 4.2% | Medium (20%) |
| Graham Number | $81.63 | -68.2% | Medium (40%) |
| EV/EBITDA | $134.16 | -47.7% | Medium (20%) |
| EV/FCF | $154.06 | -39.9% | Medium (20%) |
| Earnings Power Value | $283.40 | 10.6% | Medium (50%) |
Based on 7 out of 8 methods, JNJ appears overvalued at the current price of $256.35. The base case fair value of $154.06 implies 39.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.